<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1:	Drugs that may have their plasma concentrations increased by itraconazole</caption>
<col align="left" valign="top" width="15%"></col>
<col align="left" valign="top" width="15%"></col>
<col align="left" valign="top" width="22%"></col>
<col align="left" valign="top" width="23%"></col>
<col align="left" valign="top" width="25%"></col>
<thead>
<tr stylecode="Botrule">
<th stylecode="Lrule Rrule">Drug Class</th>
<th stylecode="Rrule">Contraindicated</th>
<th stylecode="Rrule">Not Recommended</th>
<th stylecode="Rrule">Use with Caution</th>
<th stylecode="Rrule">Comments</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">
<content stylecode="italics">Under no circumstances is the drug to be coadministered with itraconazole, and up to two weeks after discontinuation of treatment with itraconazole.</content>
</td>
<td stylecode="Rrule">
<content stylecode="italics">It is recommended that the use of the drug be avoided during and up to two weeks after discontinuation of treatment with itraconazole, unless the benefits outweigh the potentially increased risks of side effects. If coadministration cannot be avoided, clinical monitoring for signs or symptoms of increased or prolonged effects or side effects of the interacting drug is recommended, and its dosage be reduced or interrupted as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects.</content>
</td>
<td stylecode="Rrule">
<content stylecode="italics">Careful monitoring is recommended when the drug is coadministered with itraconazole. Upon coadministration, it is recommended that patients be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the interacting drug, and its dosage be reduced as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects.</content>
</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Alpha Blockers</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">tamsulosin</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Analgesics</td>
<td stylecode="Rrule">methadone</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">alfentanil, <br/>buprenorphine IV and sublingual, <br/>fentanyl, <br/>oxycodone, <br/>sufentanil</td>
<td stylecode="Rrule">
<content stylecode="bold">Methadone:</content> The potential increase in plasma concentrations of methadone when coadministered with SPORANOX<sup>®</sup> may increase the risk of serious cardiovascular events including QTc prolongation and <content stylecode="italics">torsade de pointes</content>. </td>
</tr>
<tr>
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Fentanyl: </content>The potential increase in plasma concentrations of fentanyl when coadministered with SPORANOX<sup>®</sup> may increase the risk of potentially fatal respiratory depression.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Sufentanil: </content>No human pharmacokinetic data of an interaction with itraconazole are available. <content stylecode="italics">In vitro</content> data suggest that sufentanil is metabolized by CYP3A4 and so potentially increased sufentanil plasma concentrations would be expected when coadministered with SPORANOX<sup>®</sup>.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Antiarrhythmics</td>
<td stylecode="Rrule">disopyramide, <br/>dofetilide, <br/>dronedarone, <br/>quinidine</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">digoxin</td>
<td stylecode="Rrule">
<content stylecode="bold">Disopyramide, dofetilide, dronedarone, quinidine:</content> The potential increase in plasma concentrations of these drugs when coadministered with SPORANOX<sup>®</sup> may increase the risk of serious cardiovascular events including QTc prolongation.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Antibacterials</td>
<td stylecode="Rrule">telithromycin, in subjects with severe renal impairment or severe hepatic impairment</td>
<td stylecode="Rrule">rifabutin</td>
<td stylecode="Rrule">telithromycin</td>
<td stylecode="Rrule">
<content stylecode="bold">Telithromycin:</content> The potential increase in plasma concentrations of telithromycin in subjects with severe renal impairment or severe hepatic impairment, when coadministered with SPORANOX<sup>®</sup> may increase the risk of serious cardiovascular events including QT prolongation and torsade de pointes. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Rifabutin:</content> See also under '<linkhtml href="#DIPC">Drugs that may decrease itraconazole plasma concentrations</linkhtml>'.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Anticoagulants and Antiplatelet Drugs</td>
<td stylecode="Rrule">ticagrelor</td>
<td stylecode="Rrule">apixaban, <br/>rivaroxaban</td>
<td stylecode="Rrule">coumarins, <br/>cilostazol, <br/>dabigatran</td>
<td stylecode="Rrule">
<content stylecode="bold">Ticagrelor: </content>The potential increase in plasma concentrations of ticagrelor may increase the risk of bleeding.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Coumarins:</content> SPORANOX<sup>®</sup> may enhance the anticoagulant effect of coumarin-like drugs, such as warfarin.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Anticonvulsants</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">carbamazepine</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Carbamazepine: </content>
<content stylecode="italics">In vivo</content> studies have demonstrated an increase in plasma carbamazepine concentrations in subjects concomitantly receiving ketoconazole. Although there are no data regarding the effect of itraconazole on carbamazepine metabolism, because of the similarities between ketoconazole and itraconazole, concomitant administration of SPORANOX<sup>®</sup> and carbamazepine may inhibit the metabolism of carbamazepine. See also under '<linkhtml href="#DIPC">Drugs that may decrease itraconazole plasma concentrations</linkhtml>'.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Antidiabetics</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">repaglinide, <br/>saxagliptin</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Antihelmintics and Antiprotozoals</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">praziquantel</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Antimigraine Drugs</td>
<td stylecode="Rrule">ergot alkaloids, such as dihydroergotamine, <br/>ergometrine (ergonovine), <br/>ergotamine, <br/>methylergometrine (methylergonovine)</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">eletriptan</td>
<td stylecode="Rrule">
<content stylecode="bold">Ergot Alkaloids:</content> The potential increase in plasma concentrations of ergot alkaloids when coadministered with SPORANOX<sup>®</sup> may increase the risk of ergotism, ie. a risk for vasospasm potentially leading to cerebral ischemia and/or ischemia of the extremities.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Antineoplastics</td>
<td stylecode="Rrule">irinotecan</td>
<td stylecode="Rrule">axitinib, <br/>dabrafenib, <br/>dasatinib, <br/>ibrutinib, <br/>nilotinib, <br/>sunitinib,<br/>trabectedin</td>
<td stylecode="Rrule">bortezomib, <br/>busulphan, <br/>docetaxel, <br/>erlotinib, <br/>gefitinib,<br/> imatinib, <br/>ixabepilone, <br/>lapatinib, <br/>ponatinib, <br/>trimetrexate, <br/>vinca alkaloids</td>
<td stylecode="Rrule">
<content stylecode="bold">Irinotecan:</content> The potential increase in plasma concentrations of irinotecan when coadministered with SPORANOX<sup>®</sup> may increase the risk of potentially fatal adverse events.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Antipsychotics, Anxiolytics and Hypnotics</td>
<td stylecode="Rrule">lurasidone, <br/>oral midazolam, <br/>pimozide, <br/>triazolam</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">alprazolam, <br/>aripiprazole, <br/>buspirone, <br/>diazepam, <br/>haloperidol, <br/>midazolam IV, <br/>perospirone, <br/>quetiapine, <br/>ramelteon, <br/>risperidone</td>
<td stylecode="Rrule">
<content stylecode="bold">Midazolam, triazolam</content>: Coadministration of SPORANOX<sup>®</sup> and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these  drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Pimozide:</content> The potential increase in plasma concentrations of pimozide when coadministered with SPORANOX<sup>®</sup> may increase the risk of serious cardiovascular events including QTc prolongation and <content stylecode="italics">torsade de pointes</content>. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Antivirals</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">simeprevir</td>
<td stylecode="Rrule">maraviroc, <br/>indinavir, <br/>ritonavir, <br/>saquinavir</td>
<td stylecode="Rrule">
<content stylecode="bold">Indinavir, ritonavir:</content> See also under '<linkhtml href="#DPC">Drugs that may increase itraconazole plasma concentrations</linkhtml>'.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Beta Blockers</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">nadolol</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Calcium Channel Blockers</td>
<td stylecode="Rrule">felodipine, <br/>nisoldipine</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">other dihydropyridines, <br/>verapamil</td>
<td stylecode="Rrule">
<content id="CCB" stylecode="bold">Calcium channel blockers</content> can have a negative inotropic effect which may be additive to those of itraconazole. The potential increase in plasma concentrations of calcium channel blockers when co-administered with SPORANOX<sup>®</sup> may increase the risk of  congestive heart failure. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Dihydropyridines:</content> Concomitant administration of SPORANOX<sup>®</sup> may cause several-fold increases in plasma concentrations of dihydropyridines. Edema has been reported in patients concomitantly receiving SPORANOX<sup>®</sup> and dihydropyridine calcium channel blockers.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Cardiovascular Drugs, Miscellaneous</td>
<td stylecode="Rrule">Ivabradine,<br/> ranolazine</td>
<td stylecode="Rrule">aliskiren, <br/>sildenafil, for the treatment of pulmonary hypertension</td>
<td stylecode="Rrule">bosentan, <br/>riociguat</td>
<td stylecode="Rrule">
<content stylecode="bold">Ivabradine:</content> The potential increase in plasma concentrations of ivabradine when coadministered with SPORANOX® may increase the risk of ivabradine-related adverse events, such as atrial fibrillation, bradycardia, sinus arrest and heart block.<br/>
<content stylecode="bold">Ranolazine:</content> The potential increase in plasma concentrations of ranolazine when coadministered with SPORANOX<sup>®</sup> may increase the risk of serious cardiovascular events including QTc prolongation.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Diuretics</td>
<td stylecode="Rrule">eplerenone</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Eplerenone:</content> The potential increase in plasma concentrations of eplerenone when coadministered with SPORANOX<sup>®</sup> may increase the risk of hyperkalemia and hypotension.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Gastrointestinal Drugs</td>
<td stylecode="Rrule">cisapride</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">aprepitant</td>
<td stylecode="Rrule">
<content stylecode="bold">Cisapride:</content> The potential increase in plasma concentrations of cisapride when coadministered with SPORANOX<sup>®</sup> may increase the risk of serious cardiovascular events including QTc prolongation.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Immunosuppressants</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">everolimus, <br/>temsirolimus</td>
<td stylecode="Rrule">budesonide, <br/>ciclesonide, <br/>cyclosporine, <br/>dexamethasone, <br/>fluticasone, <br/>methylprednisolone, <br/>rapamycin (also known as sirolimus), <br/>tacrolimus</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Lipid Regulating Drugs</td>
<td stylecode="Rrule">lovastatin, <br/>simvastatin</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">atorvastatin</td>
<td stylecode="Rrule">The potential increase in plasma concentrations of atorvastatin, lovastatin, and simvastatin when coadministered with SPORANOX<sup>®</sup> may increase the risk of skeletal muscle toxicity, including rhabdomyolysis.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Respiratory Drugs</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">salmeterol</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Urological Drugs</td>
<td stylecode="Rrule">fesoterodine, in subjects with moderate to severe renal impairment, or moderate to severe hepatic impairment,<br/>solifenacin, in subjects with severe renal impairment or moderate to severe hepatic impairment</td>
<td stylecode="Rrule">darifenacin, <br/>vardenafil</td>
<td stylecode="Rrule">fesoterodine. <br/>oxybutynin, <br/>sildenafil, for the treatment of erectile dysfunction, <br/>solifenacin, <br/>tadalafil, <br/>tolterodine</td>
<td stylecode="Rrule">
<content stylecode="bold">Fesoterodine:</content> The potential increase in plasma concentrations of the fesoterodine active metabolite may be greater in subjects with moderate to severe renal impairment, or moderate to severe hepatic impairment, which may lead to an increased risk of adverse reactions.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Solifenacin:</content> The potential increase in plasma concentrations of solifenacin in subjects with severe renal impairment or moderate to severe hepatic impairment, when coadministered with SPORANOX<sup>®</sup> may increase the risk of serious cardiovascular events including QT prolongation.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Other</td>
<td stylecode="Rrule">colchicine, in subjects with renal or hepatic impairment</td>
<td stylecode="Rrule">colchicine, <br/>conivaptan, <br/>tolvaptan</td>
<td stylecode="Rrule">cinacalcet</td>
<td stylecode="Rrule">
<content stylecode="bold">Colchicine:</content> The potential increase in plasma concentrations of colchicine when coadministered with SPORANOX<sup>®</sup> may increase the risk of potentially fatal adverse events.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">
<content stylecode="bold">Conivaptan and Tolvaptan: </content>A safe and effective dose of either conivaptan or tolvaptan has not been established when coadministered with SPORANOX<sup>®</sup>.</td>
</tr>
</tbody>
</table>